Filed with ASX · · 4 pages · English
Imugene Ltd has announced amendments to its existing convertible notes with CVI Investments, Inc. to enhance its cash flow position and provide more flexible terms under current market conditions. The amendments introduce a conditional right for Imugene to redeem the notes prior to maturity, subject to CVI's consent and certain conditions. Imugene's Executive Chairman stated that these changes will help manage the payments associated with the convertible notes while preserving cash for clinical programs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX Announcement Imugene and CVI agree positive amendments to Convertible Notes 3 November 2026 – Imugene Limited (ASX: IMU) (Imugene or the Company), a clinical stage immuno-oncology company, 8is pleased to announce that it has entered into Deeds of Amendment (the Amendments) with CVI...
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene